Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of glycyrrhetinic acid and glycyrrhizic acid in preparing medicaments for preventing or treating pulmonary fibrosis

A technology for pulmonary fibrosis and glycyrrhetic acid, which is applied in the application field of glycyrrhetic acid and glycyrrhizic acid in the preparation of medicines for preventing or treating pulmonary fibrosis, and achieves the effects of exact curative effect and low toxicity

Active Publication Date: 2010-12-22
XIAMEN LUJIA BIOTECH
View PDF0 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the effect of glycyrrhetinic acid and glycyrrhizic acid on the prevention and treatment of pulmonary fibrosis (PF) has not been reported yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of glycyrrhetinic acid and glycyrrhizic acid in preparing medicaments for preventing or treating pulmonary fibrosis
  • Application of glycyrrhetinic acid and glycyrrhizic acid in preparing medicaments for preventing or treating pulmonary fibrosis
  • Application of glycyrrhetinic acid and glycyrrhizic acid in preparing medicaments for preventing or treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1 Effects of glycyrrhetinic acid and glycyrrhizic acid on the production of inflammatory cytokines in Raw 264.7 macrophages induced by irradiation

[0047] Raw264.7 macrophages were cultured in 24-well plates, and glycyrrhetinic acid and glycyrrhizic acid of different concentrations were added immediately after 4Gy irradiation, and the cell supernatant was collected after 48 hours, and the contents of various cytokines were measured by ELISA. Both glycyrrhetinic acid and glycyrrhizic acid can inhibit the increase of macrophage inflammatory cytokines IL-6 and TNF-α after irradiation stimulation (see figure 1 , figure 2 ). The results showed that glycyrrhetinic acid and glycyrrhetinic acid had the effect of anti-radiation inflammation, which may be related to its anti-radiation injury.

Embodiment 2

[0048] Example 2 Effects of glycyrrhetinic acid and glycyrrhizic acid on acute radiation-induced lung injury in mice

[0049] 6-week-old female C57BL / 6 mice were randomly divided into 7 groups: (1) normal control group; (2) model solvent group; (3) Celebrex group, Celebrex (Celebrex) 30mg / kg gavage; (4) ) Dexamethasone group, dexamethasone 3mg / kg intraperitoneal injection; (5) Amifostine group, Amifostine 200mg / kg intravenous injection; (6) Glycyrrhetinic acid group, glycyrrhetinic acid 40mg / kg gavage; ( 7) Glycyrrhizic acid group, 40 mg / kg glycyrrhizic acid orally. After the mice were fixed with a special device, the whole lung was irradiated with 15Gy X-rays at a time. Different drugs were administered within 2 hours after irradiation, once a day, and then once every other day after a week, for 17 consecutive days. Rats were killed on day 2.5 and day 17 to take lungs, and some of them were reserved for pathological examination. The remaining lungs were weighed and made int...

Embodiment 3

[0050] Example 3 Effect of Glycyrrhetinic Acid on Chronic Radiation-induced Lung Injury

[0051] 6-week-old female C57BL / 6 mice were randomly divided into 6 groups: (1) normal control group (0 Gy); (2) model solvent group; (3) Celebrex group, Celebex (Celebrex) 30mg / kg infusion Stomach; (4) Dexamethasone group, intraperitoneal injection of dexamethasone 3mg / kg; (5) Amifostine group, intravenous injection of Amifostine 200mg / kg; (6) Glycyrrhetinic acid group, glycyrrhetinic acid 40mg / kg Gavage. After the mice were fixed with a special device, the whole lung was irradiated with 18 Gy or 15 Gy X-rays at a time. Different drugs were given within 2 hours after irradiation, once a day, and then every other day for several weeks. 4 to 7.5 months after irradiation, the mice were placed in a special restraint tube, and after the mice were quiet for 5 minutes, the mice in the tube entered the Havard Rodent ventilator breath recorder, and the tracer measured the number of breaths per m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of glycyrrhetinic acid and glycyrrhizic acid in preparing medicaments for preventing or treating pulmonary fibrosis. The glycyrrhetinic acid or the glycyrrhizic acid can be used for reducing collagen deposition of lung tissues, decreasing or delaying the occurrence of the pulmonary fibrosis, improving lung compliance and further improving pulmonary functions through inhibiting acute or chronic inflammation reaction. The medicaments prepared from the glycyrrhetinic acid or the glycyrrhizic acid for resisting the pulmonary fibrosis has the advantages of good curative effect and low toxicity during administration in long term, can be used as medicaments for preventing or treating fibrosis, and can also be used as medicines or health care products as well as foods or food additives for preventing or treating the pulmonary fibrosis.

Description

technical field [0001] The invention relates to glycyrrhetinic acid and the application of glycyrrhizic acid in the preparation of medicines for preventing or treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis (PF) is a disease characterized by diffuse pneumonia and alveolar structural disorder, which eventually leads to pulmonary interstitial fibrosis. pathological features. Interstitial lung disease can include primary lung disease, systemic rheumatic disease, drug or radiation therapy, environmental or occupational disease, pulmonary angiogenesis, alveolar stasis disease and genetic disease. kind. According to its etiology, it can be divided into two types: idiopathic and secondary. Its common feature is that the normal alveolar structure is damaged by inflammation caused by various reasons, that is, alveolitis; instead, the accumulation of collagen scar tissue repairs the damage, that is, fibrosis occurs, and the lung tissue gradually loses ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61K31/56A61P1/16A23L1/29A23L1/30A23L33/105
Inventor 张鲁榕张纬建杨善民许建华
Owner XIAMEN LUJIA BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com